文献速递心律失常血脂与心血管预防

ENGAGE AF-TIMI 48 试验中依度沙班在女性与男性房颤患者中的疗效与安全性比较

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
PubMed 文献 · Circulation · 2021-02-15

本研究基于 ENGAGE AF-TIMI 48 试验,比较依度沙班在 8040 名女性与 13 065 名男性房颤患者中的疗效与安全性。结果显示高剂量依度沙班在男女中降低卒中/体循环栓塞风险相似,但女性出血性卒中、颅内出血及危及生命或致命性出血的下降幅度大于男性。

要点

  • 高剂量依度沙班降低卒中/体循环栓塞风险在男女中相似(女性 HR 0.87,男性 HR 0.87)。
  • 女性使用高剂量依度沙班的大出血风险降低幅度与男性相似(女性 HR 0.74,男性 HR 0.84)。
  • 女性使用高剂量依度沙班在出血性卒中、颅内出血及危及生命或致命性出血方面的获益大于男性。

核心结论

  • 尽管女性基线内源性因子 Xa 活性更高,依度沙班在男女中达到的抗凝强度相似。
  • 高剂量依度沙班在女性中降低出血性卒中和多种严重出血结局的幅度大于男性,而疗效在男女中相似。

研究设计与样本

  • ENGAGE AF-TIMI 48 试验随机分配 21 105 例房颤且 CHADS2 评分≥2 的患者(8040 例女性)至 высок剂量依度沙班、低剂量依度沙班或华法林组。
  • 主要疗效终点为卒中或体循环栓塞事件的复合终点,主要安全性终点为 ISTH 定义的大出血。

主要发现

  • 与男性相比,女性年龄更大、体重更低,高血压和肾功能不全比例更高,吸烟、饮酒、糖尿病和冠心病比例更低。
  • 女性治疗前内源性因子 Xa 活性显著高于男性(92.5% vs 86.1%,P<0.001)。
  • 高剂量依度沙班相比华法林降低卒中/体循环栓塞风险在女性(HR 0.87,95%CI 0.69-1.11)和男性(HR 0.87,95%CI 0.71-1.06)中相似(P-interaction=0.97)。
  • 高剂量依度沙班相比华法林降低大出血风险在女性(HR 0.74,95%CI 0.59-0.92)和男性(HR 0.84,95%CI 0.72-0.99)中相似(P-interaction=0.34)。
  • 女性使用高剂量依度沙班相比华法林在出血性卒中(HR 0.30,95%CI 0.15-0.59 vs 男性 HR 0.70,95%CI 0.46-1.06)、颅内出血(HR 0.20,95%CI 0.10-0.39 vs 男性 HR 0.63,95%CI 0.44-0.89)和危及生命或致命性出血(HR 0.25,95%CI 0.15-0.42 vs 男性 HR 0.72,95%CI 0.54-0.96)的降低幅度大于男性(各 P-interaction<0.05)。

临床怎么用

  • 高剂量依度沙班在女性和男性房颤患者中均可有效预防卒中/体循环栓塞,且女性在严重出血结局方面可能获益更大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Female sex is an independent risk factor for stroke and systemic embolic events in patients with atrial fibrillation. This study aimed to examine the efficacy and safety profile of edoxaban in women versus men. METHODS: The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) randomly assigned 21 105 patients (8040 women) with atrial fibrillation and CHADS2 score ≥2 either to a higher-dose edoxaban regimen, a lower-dose edoxaban regimen, or warfarin. The primary end points of the trial were the composite of stroke or systemic embolic events (efficacy), and International Society on Thrombosis and Haemostasis-defined major bleeding (safety). RESULTS: In comparison with men, women were older, had lower body weight, were more likely to have hypertension and renal dysfunction, but less likely to smoke, drink alcohol, or have diabetes or coronary artery disease. Pretreatment endogenous factor Xa activity was significantly higher in women than in men (92.5% versus 86.1%, P<0.001). Treatment with edoxaban in women resulted in greater peak edoxaban concentration and inhibition of endogenous factor Xa in comparison with men, resulting in similar endogenous factor Xa activity between the sexes 2 to 4 hours after dose. Treatment with higher-dose edoxaban regimen (versus warfarin) resulted in similar reduction in the risk of stroke/systemic embolic events (women: hazard ratio [HR], 0.87 [0.69-1.11], men: HR, 0.87 [0.71-1.06]; P-interaction=0.97) and major bleeding (women: HR, 0.74 [0.59-0.92], men: HR, 0.84 [0.72-0.99]; P-interaction=0.34) in women and men. However, women assigned to higher-dose edoxaban regimen experienced greater reductions in hemorrhagic stroke (HR, 0.30 [95% CI, 0.15-0.59] versus HR, 0.70 [95% CI, 0.46-1.06]), intracranial bleeding (HR, 0.20 [95% CI, 0.10-0.39] versus HR, 0.63 [95% CI, 0.44-0.89]), and life-threatening or fatal bleeding (HR, 0.25 [95% CI, 0.15-0.42] versus HR, 0.72 [95% CI, 0.54-0.96]) than men (each P-interaction<0.05). CONCLUSIONS: Despite many differences in baseline characteristics between women and men and higher baseline endogenous factor Xa levels in women, the intensity of anticoagulation achieved with edoxaban between the sexes was similar. Treatment with higher-dose edoxaban regimen resulted in an even greater reduction in hemorrhagic stroke and several serious bleeding outcomes in women than in men, whereas the efficacy profile was similar between sexes.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zelniker TA, Ardissino M, Andreotti F, et al. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation. 2021. PMID: 33587659. doi:10.1161/CIRCULATIONAHA.120.052216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。